|
- Illumina | Sequencing and array solutions to fuel genomic discoveries
Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics
- About Us | A global leader in genomics - Illumina
We are Illumina We are a global genomics and human health leader innovating the future of precision health We develop DNA sequencing and array-based life sciences technologies to enable boundless research discovery and personalized health
- Why The Narrative Around Illumina Is Shifting After Recent Analyst . . .
Illumina's stock has seen a modest increase in its Fair Value Estimate, rising from $113 58 to $117 74 This reflects improved analyst confidence in the company's future prospects This change
- Statement Regarding Illumina’s Decision to Divest Grail
Illumina’s decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality tests for patients and physicians, ultimately saving lives
- Illumina completes $500 million public offering of 4. 750% notes due . . .
Illumina, Inc (NASDAQ:ILMN) announced Tuesday that it has completed a public offering of $500 million in aggregate principal amount of 4 750% notes due 2030 The company stated in a press release that the notes will mature on December 12, 2030, and interest will be paid semi-annually at a rate of 4 750% per annum Illumina expects to use the net proceeds from the offering for general
- Genomics products | Illumina
Illumina offers a broad range of sequencing and microarray products for diverse genomic analysis applications
- Illumina, Inc. $ILMN Shares Purchased by M G PLC - MarketBeat
M G PLC raised its holdings in Illumina, Inc (NASDAQ:ILMN - Free Report) by 130 6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission The fund owned 558,503 shares of the life sciences company's stock after acquiring an additional
- When cybersecurity becomes a compliance obligation: Lessons from the . . .
The government argued Illumina falsely certified compliance with cybersecurity standards, making its claims for payment "false" under federal law The settlement arose from a whistleblower suit filed by a former Illumina director, who will receive nearly USD1 9 million as part of the resolution
|
|
|